A 7-month progress report of using finasteride and minoxidil, as well as keto dieting and derma stamping; the discussion also touched on RU58841 and its potential side effects.
User "Number_Worried00" is using a treatment stack for hair loss, including Minoxidil, Finasteride, Dutasteride, Estradiol, Cetirizine, and Pyrilutamide. Another user suggests that if the cause is vitamin deficiency or inflammation, the stack may not be effective.
Amino acids like lysine, methionine, and cysteine may help with androgenetic alopecia when taken in high doses along with a DHT blocker. Users discuss combining these with treatments like Minoxidil, finasteride, and RU58841.
Microneedling for hair loss and its potential long-term effects. Some users believe it can cause fibrosis and scar tissue if done too frequently or deeply, while others claim it has improved their hair loss when done correctly. There is limited scientific research on the topic.
A 32-year-old user shared progress pictures after using finasteride for 12 months, starting with 0.25g for 5 months and then 0.5g for 7 months. They have not yet added minoxidil or dermarolling and will update at the one-year mark.
HairClone plans to start hair multiplication services in 2022. Users discuss various treatments like Minoxidil, finasteride, PRP, and hair cloning, expressing both hope and skepticism about the technology and its costs.
The conversation discusses switching from a dermaroller to a dermastamp for microneedling, with recommendations on technique and frequency to avoid bleeding. The user also uses minoxidil and dutasteride for hair loss treatment.
The user is considering a second hair transplant after previous treatments with finasteride and minoxidil failed to stop hair loss. Suggestions include trying dutasteride, oral minoxidil, scalp micropigmentation, or shaving the head.
The conversation discusses the potential benefits and risks of using Methionine and Glycine for hair loss, with concerns about cancer risk if not balanced properly. The user seeks opinions on these amino acids for hair health and overall benefits.
P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.
The user is experiencing hair regrowth with oral minoxidil and dutasteride but still has fragile hairs that easily pluck out from the front center. Despite improvements, the user is concerned about the persistent fragility and shedding of these hairs.
A user is considering a $5,295 one-year hair loss program from HairClub/Bosley, which includes treatments like finasteride, minoxidil, and a DNA test to personalize treatment. Opinions are mixed, with some suggesting cheaper alternatives like standard medications and questioning the value of the program.
Follistatin, known for inhibiting myostatin and promoting muscle growth in mice, is being discussed as a potential treatment for hair loss. Specific treatments mentioned include Minoxidil, Finasteride, and RU58841.
New company Amplifica receives $11.8 million for hair loss product development, co-founded by Dr. Maksim Plikus and William Rassman. Users discuss undisclosed product candidates and application methods.
The conversation is about using PTD-DBM and valproic acid for hair loss. The user is inquiring about the dosage of these treatments, noting that valproic acid is used at a 7.5% solution.
The user showed progress in hair regrowth using topical Minoxidil, oral Finasteride, and derma rolling with tretinoin. They seek advice on achieving Norwood 1 and the number of grafts needed for hairline restoration.
The user is asking about the difference between a dermaroller and a dermastamp for hair loss treatment, noting that the dermaroller tangles and pulls out hair. They are seeking advice on which tool is better for long hair.
The conversation discusses using peptides BPC-157 and TB-500, combined with microneedling, to potentially enhance hair regrowth. The user plans to try BPC-157 due to its lower cost and reports of hair growth, despite limited human trials and concerns about side effects from other treatments like minoxidil and finasteride.
A user's hair loss treatment progress over the last 6 months using finasteride, minoxidil and dermarolling; other users have commented to ask questions or share their own experiences.
Dr. Tsuji and Riken announced a hair cloning cure with a 98.9% success rate, expected to be released in 10 years. Users expressed hope and skepticism about the affordability and timeline of the treatment.
An 18-year-old experienced severe side effects, including heart palpitations and high blood pressure, after using RU58841 once, leading to a referral to cardiology for suspected left ventricular hypertrophy. The user regrets using RU58841 and seeks advice on recovery, while others suggest preexisting conditions or genetic predispositions may be factors.
Whey protein isolate may worsen androgenetic alopecia (AGA) due to its potential to increase DHT levels, but finasteride use has helped maintain hair. Some users suggest avoiding protein supplements due to possible contaminants and additives that could affect hair health.
A person had a hair transplant at Diamond Hair Clinic with Dr. Mehmet Demircioglu using the Sapphire FUE method with 4500 grafts. They are using Duasteride, oral and topical Minoxidil, and vitamins for recovery and hair growth.
The conversation discusses CRISPR-on & CRISPR-off as a potential cure for baldness, contrasting it with hair cloning and other treatments like Minoxidil, finasteride, and RU58841. It also mentions the potential of mRNA for gene expression control and the prioritization of gene editing for severe genetic conditions.
The conversation is about experiences with GHK-Cu Copper and AHK-Cu Copper for hair regrowth and thickening. One user expressed skepticism about its effectiveness.
PP405 cannot restore extracted hair follicles after a transplant as they are removed, not dormant. Combining verteporphin with wounding and PP405 is suggested but not confirmed effective.
The conversation discusses updates on hair loss treatments, specifically GT20029, PP405, and a rumored injectable peptide from UT. GT20029 is seen as a promising treatment expected within 5-7 years.
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
Treating hair loss with finasteride, dutasteride and minoxidil, as well as micro-needling, potentially using research chemicals such as Pyril and Senzu Beans.